Actuality: the important component of COPD pathogenesis is the activation of lipid peroxidation and disorders of immune system. Today it is very important to prescribe for COPD patients preparations which would provide the activation mechanisms of self-regulation of antioxidant systems, adequate immune response, improving the barrier function of the mucous membrane of the bronchi.
The aim of this study was to improve the treatment of COPD patients by mexidol that has both antioxidant and immunomodulatory properties expressed, achieving patient compliance and comfort treatment, minimizing the number of drugs.
Matherials and methods: there were given data of immunological blood analysis in 38 patients with intensifying of COPD of І–ІІ stages. The standard therapy was conducted in 20 patients, and on the background of standard treatment mexidol was added during 30 days in 18 patients. Application of mexidol 500 mg/day for the patients with COPD renders the immunomodulated activity mainly on the cellular link of the immune system, assists the improvement of elimination of bacterial agents, increase of antigenpresented cells and citotoxic activity of natural killers.
Conclusions: immunomodulative therapy with the mexidol usage is considered to be a nosotropic adding to the standard treatment of COPD patients on the I–II stages.